Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire

Kathleen W Wyrwich1
Holly Yu2
Reiko Sato2
John H Powers3
1Evidera, Inc., Bethesda, MD, USA; 2Pfizer Inc., Collegeville, PA, USA; 3George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Background: Millions of older adults who develop community-acquired pneumonia (CAP) each year survive, but there is a large knowledge gap on the burden of CAP and the recovery process in survivors from the patient perspective.

Methods: The newly developed CAP Burden of Illness Questionnaire was administered through a Web survey to a nationwide sample of US adults aged ≥50 years who were recently diagnosed with CAP. Survey respondents with unresolved symptoms or other CAP-related health problems completed a second survey 30 days later; a third survey was completed another 30 days later by respondents with unresolved symptoms or problems. Nationally representative results describing the average time to recovery of symptoms and other CAP-related problems were achieved using post-stratification weights.

Results: Five hundred participants completed the initial survey. The time to resolution for the CAP symptoms of weakness, shortness of breath, and tiredness exceeded 3 weeks on average. There was an average of 13 days of absenteeism, and 3 weeks (mean = 21 days) before achieving full work/activity productivity after CAP. For participants with health conditions that worsened from pneumonia, chronic emphysema and chronic obstructive pulmonary disease took the longest to return to baseline (mean = 60 and 52.4 days, respectively).

Conclusion: The results from this study demonstrate that older adults surviving a CAP episode experience a significant multi-symptom illness with long recovery periods to achieve pre-CAP health and productivity. These findings highlight the need for further research on effective clinician–patient communication, the need for patient-centered outcomes in clinical trials for CAP therapeutics, adequate home care during the recovery process, and the pursuit of CAP prevention strategies.

Keywords: burden of illness, community-acquired pneumonia, symptoms, patient-reported outcomes, longitudinal study, health-related quality of life

Introduction
Approximately, 950,000 cases of community-acquired pneumonia (CAP) occur in the USA each year in adults <65 years of age;1 concurrently, another 1.3 million cases occur in older adults ≥65 years of age.2 CAP is defined as pneumonia contracted in the community rather than in a hospital or nursing home setting, or while on a ventilator.3 With the incidence and severity of CAP increasing notably with age,4 pneumonia remains the leading cause of infectious disease mortality in the USA.5 These data
indicate that millions of older adults in the USA survive this disease each year, leaving a large knowledge gap on the burden of CAP and the recovery process in survivors from the patient perspective.

Prior studies evaluating the time to resolution of CAP symptoms have focused on a very limited number of indicators selected and worded by physicians.6,7 While returning to work or other usual activities are important milestones in the recovery from CAP,8-10 diminished productivity during the CAP recovery process may extend beyond absenteeism. There is a need to better understand the broad range of problems associated with CAP recovery based on the patients’ experiences that are not measured in generic health status instruments,11,12

Therefore, the CAP Burden of Illness Questionnaire (CAP-BIQ) was developed and refined through in-depth concept elicitation and cognitive debriefing interviews with adults ≥50 years of age who had recently been diagnosed with CAP.13 This report provides results across three successive monthly survey administrations up to 180 days after CAP diagnosis, detailing the length of time that older adults in the USA have CAP symptoms as well as CAP’s detrimental effects on other health conditions and productivity.

Methods
Study design, participants, and outcome measures
The CAP-BIQ was designed using the methodology recommended by the US Food and Drug Administration14 for the development of patient-reported outcome measures. Details on the development and testing of this survey instrument are available elsewhere.13 The questionnaire was administered in three waves, each 30 days after the preceding wave (Wave 1, Wave 2, and Wave 3), to measure the time course of CAP symptoms until resolution. Participants with unresolved CAP symptoms or related CAP problems noted at Wave 1 were followed 30 days later (Wave 2); those with any unresolved CAP symptoms or problems at Wave 2 were followed for an additional 30 days (Wave 3). The full CAP-BIQ is available on the Journal’s website at http://www.dovepress.com/get_supplementary_file.php?F=85779.pdf.

Participants were recruited through an e-mail invitation from the YouGov® panel of US adults age ≥50 years. For inclusion, participants were required to: have been told by a doctor or nurse that they had pneumonia within the past 120 days; self-report having a chest X-ray or computed tomography (CT) scan around the time they were informed of their diagnosis; be able to read English; and be willing to provide informed consent. To refine CAP identification, participants were excluded if they had been admitted to the hospital for any reason during the 2 weeks prior to their diagnosis or if they resided in a nursing home or assisted care facility. Enrollment was closed after the 500th participant completed the Wave 1 assessment; a sample size of 500 was chosen to give adequate precision on descriptive statistics. This study was conducted in accordance with the amended Declaration of Helsinki. An independent ethics and review committee (Ethical and Independent Review Services, Independence, MO, USA) approved the protocol, and written informed consent was obtained from all the participants.

Statistical analyses
Sample weighting was used to construct a nationally representative sample of the US adults aged ≥50 years. The post-stratification weights were calculated using matching variables for age, race/ethnicity, and education. Student’s t-tests were used to compare mean values, and chi-square tests for categorical data inferences. For time to resolution of CAP-related symptoms or other issues, the mean, median, and interquartile ranges, as well as P-values for the mean inferential comparisons were reported. As exploratory analyses, results were stratified to compare by: age group (50–64 and ≥65 years old), hospitalization status (yes/no), and risk group assignment for developing pneumonia (high risk: the presence of asthma, COPD, chronic bronchitis, chronic emphysema, heart disease, diabetes, or other immunocompromised conditions; low risk: none of the high-risk comorbid conditions).15,16 Productivity and caregiver assistance results were stratified based on self-reported employment status. All the group comparison analyses incorporated a Bonferroni correction to alpha to address multiplicity. The analyses were performed in SAS version 9.1.3.

Results
The sociodemographic characteristics for all participants in the Wave 1 (baseline) survey using the weighted sample are fully described elsewhere.13 Briefly summarizing those results, 45% were male, the average age was 62.4 years old, the majority of participants reported living with a partner (79.5%), and 89.2% selected White as their race. The mean number of days between CAP diagnosis and Wave 1 CAP-BIQ completion was 56.9 days. The mean hospital stay due to pneumonia was 6.8 days, and 91.4% of these patients were hospitalized on the day of diagnosis. The hospitalized group was older and had a greater percentage of participants with COPD, chronic emphysema, heart disease, and diabetes than the nonhospitalized group (P<0.001). High-risk participants...
were more likely to have high blood pressure, and more than twice as likely to be hospitalized compared to the low-risk group ($P<0.001$).

### Symptom resolution

Length of time until symptom resolution for all participants who experienced at least 1 day with a symptom is reported in Table 1. The mean and median duration for fever (feeling warm), chills, and sweats was less than a week, whereas the mean time for tiredness, weakness, and shortness of breath were at least 3 weeks. The other ten symptoms measured in this study persisted generally for approximately 1–2 weeks. The interquartile ranges for cough, body aches, wheezing, and trouble sleeping show that, for at least a quarter of the sample, it took nearly 3 weeks to achieve symptom resolution (Table 1).

Only fever/warmth and chills differed significantly ($P\leq 0.001$) between the age groups, with the younger group experiencing the symptoms on average approximately 1–3 days longer compared to the older group. Low- and high-risk groups had significant differences only in the duration of chills and sweats, with longer mean times (2–3 days) observed for the low-risk group. Fever lasted nearly twice as long on average in the nonhospitalized group compared to those who were hospitalized, but significant differences in mean symptom duration between these two groups indicated an overall longer recovery time for the hospitalized group for tiredness, body aches, and weakness.

### Time to resolution of health conditions worsened by pneumonia

For those who experienced a worsening of specific health conditions due to pneumonia, the means, medians, and interquartile ranges for number of days to return to baseline are reported in Table 2. Patients with chronic emphysema had the longest duration to return to baseline (mean/median =60/65 days) followed by COPD (52/44 days); the 75th percentile levels for both of these groups were nearly 3 months (89 days). In the subgroup with COPD, the younger group took longer to return to their baseline COPD condition than the older age group ($P=0.004$), as did hospitalized participants compared to nonhospitalized participants ($P=0.025$), although these differences did not reach statistical significance when adjusted for multiplicity ($P<0.003$).

### CAP impacts on productivity

CAP impacts on work productivity and the need for additional help are presented in Table 3. There was a greater proportion of nonemployed versus employed participants who were hospitalized; however, a greater proportion of the employed group missed work (92.5%) compared to the proportion of the nonemployed group who missed their usual daily activities (74.1%; $P<0.001$). Those who missed days of work or usual daily activities were away on average for 13 days. Moreover, the mean time before achieving full work/activities productivity took nearly 3 weeks (20.1 days), and differed between those who were employed (14.2 days) and those who were not (24.3 days; $P<0.001$). As reported in Wyrwich et al (2013), 77.4% of participants reported at Wave 1 on the need for help with their care from family or friends during their bout with CAP.

On average, participants receiving this assistance had help for nearly 2 weeks (Table 3).

### Discussion

This study evaluated the contemporary experience of the disease course of CAP in older adults in the USA by documenting the burden of illness in CAP survivors up to 180 days after diagnosis from the patient’s perspective. Use of a newly developed, disease-specific measure based on what patients themselves described as important allowed greater detail on the presence, duration, and impact of CAP symptoms.

The key findings demonstrate that CAP patients experience a wide variety of systemic and respiratory symptoms that also impact the course of other comorbid illnesses. The results also show that symptoms and impacts of symptoms can last for days to months after onset of illness, imposing a burden on patients and on their caregivers and/or partners. Of the 16 symptoms measured, half took more than 2 weeks, on average, to resolve; the time to resolution for weakness, shortness of breath, and tiredness exceeded 3 weeks. There was also a delay of approximately 3 weeks in achieving full productivity at work or usual activities.

The length of time to resolution for most longer-lasting symptoms did not differ between participants in the younger and older age groups, or between the low- and high-risk groups. However, for tiredness, body aches, weakness, and trouble sleeping, resolution was nearly 1 week longer for those who were hospitalized compared to those who were not hospitalized. In contrast, early-resolving symptoms of fever/warmth, sweats, or chills lasted longer in nonhospitalized or younger, and low-risk subgroups compared to their respective counterparts. Because CAP is caused by pathogenic organisms infecting the pulmonary parenchyma with resultant host inflammatory response, the relatively long duration of some symptoms may reflect prolonged host response that...
### Table 1: Days until symptom resolution among participants who reported at least 1 day with symptom

<table>
<thead>
<tr>
<th>Symptom (with symptom at diagnosis of CAP)</th>
<th>All N=500</th>
<th>Age 50–64 N=289</th>
<th>Age 65+ N=211</th>
<th>P-value for comparison of mean time with symptom</th>
<th>Nonhospitalized N=299</th>
<th>Hospitalized N=201</th>
<th>P-value for comparison of mean time with symptom</th>
<th>Low risk N=137</th>
<th>High risk N=363</th>
<th>P-value for comparison of mean time with symptom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever/warmth (67.4%)</td>
<td>4.3, 2 [2, 7]</td>
<td>4.9, 2 [2, 7]</td>
<td>3.2, 2 [1, 2]</td>
<td>0.038</td>
<td>5.3, 2 [2, 7]</td>
<td>2.7, 2 [1, 2]</td>
<td>0.001</td>
<td>5.1, 2 [1, 7]</td>
<td>3.9, 2 [1, 7]</td>
<td>0.154</td>
</tr>
<tr>
<td>Chills (64.9%)</td>
<td>4.4, 2 [1, 7]</td>
<td>5.4, 2 [2, 7]</td>
<td>2.5, 2 [1, 2]</td>
<td>0.001</td>
<td>4.7, 2 [2, 7]</td>
<td>3.9, 2 [1, 2]</td>
<td>0.405</td>
<td>6.3, 2 [1, 7]</td>
<td>3.7, 2 [1, 7]</td>
<td>0.006</td>
</tr>
<tr>
<td>Mucus or phlegm (81.6%)</td>
<td>15.3, 7 [7, 15]</td>
<td>13.8, 7 [7, 14]</td>
<td>17.3, 7 [7, 20]</td>
<td>0.096</td>
<td>15.6, 7 [7, 19]</td>
<td>14.8, 7 [7, 14]</td>
<td>0.721</td>
<td>17.6, 14 [7, 21]</td>
<td>14.4, 7 [7, 14]</td>
<td>0.165</td>
</tr>
<tr>
<td>Weak appetite (82.2%)</td>
<td>14, 7 [2, 14]</td>
<td>13.3, 7 [2, 14]</td>
<td>15.2, 7 [2, 14]</td>
<td>0.313</td>
<td>15.7 [7, 14]</td>
<td>12.6, 7 [2, 14]</td>
<td>0.208</td>
<td>15.7, 14 [7, 18]</td>
<td>13.4, 2 [14]</td>
<td>0.275</td>
</tr>
<tr>
<td>Gastric symptoms (34.5%)</td>
<td>9.2, 7 [2, 8]</td>
<td>8.4, 7 [2, 7]</td>
<td>11.1, 7 [7, 14]</td>
<td>0.265</td>
<td>10.1, 7 [2, 14]</td>
<td>8.1, 7 [2, 8]</td>
<td>0.356</td>
<td>9.6, 7 [2, 14]</td>
<td>9.1, 7 [2, 8]</td>
<td>0.843</td>
</tr>
</tbody>
</table>

**Notes:** For those without symptom resolution, the time since CAP diagnosis to last survey was used in this calculation; low risk, none of the high-risk comorbid conditions listed in the high-risk description: chronic bronchitis, chronic emphysema, heart disease, diabetes, or other immunocompromised conditions.

**Abbreviation:** CAP, community-acquired pneumonia.
<table>
<thead>
<tr>
<th>Health condition (with health condition worsened by CAP)</th>
<th>All N=500</th>
<th>Age 50–64 N=289</th>
<th>Age 65+ N=211</th>
<th>P-value for comparison of mean time with worsened health condition</th>
<th>Non hospitalized N=299</th>
<th>Hospitalized N=201</th>
<th>P-value for comparison of mean time with worsened health condition</th>
<th>Low risk(^b)</th>
<th>High risk(^c)</th>
<th>P-value for comparison of mean time with worsened health condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD (24.4%)</td>
<td>52.4, 44 [7–89]</td>
<td>65.2, 69 [21–102]</td>
<td>39.5, 14 [7–74]</td>
<td>0.004</td>
<td>40.1, 14 [7–76]</td>
<td>60.6, 69 [14–98]</td>
<td>0.025</td>
<td>–</td>
<td>52.4, 44 [7–89]</td>
<td>NA</td>
</tr>
<tr>
<td>Chronic emphysema (8.6%)</td>
<td>60, 65 [7–89]</td>
<td>67.8, 69 [44–114]</td>
<td>41.2, 18 [7–89]</td>
<td>0.114</td>
<td>45.5, 40 [2–77]</td>
<td>70.1, 78 [55–89]</td>
<td>0.11</td>
<td>–</td>
<td>60, 65 [7–89]</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Notes:** For those without resolution, the time since CAP diagnosis to last survey was used in this calculation; \(^a\)low risk, none of the high-risk comorbid conditions listed in the \(^b\)high-risk description: COPD, chronic bronchitis, chronic emphysema, heart disease, diabetes, or other immunocompromised conditions.

**Abbreviations:** CAP, community-acquired pneumonia; NA, not applicable.
Table 3 Impact of community-acquired pneumonia on absenteeism, productivity, and help from caregiver by employment status

<table>
<thead>
<tr>
<th>Impacts on productivity and need for additional help</th>
<th>All N=500</th>
<th>Employed N=161</th>
<th>Not employed N=339</th>
<th>P-value for comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>% hospitalized</td>
<td>40.29%</td>
<td>29.98%</td>
<td>45.19%</td>
<td>0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>% who missed work or other usual daily activities</td>
<td>79.99%</td>
<td>92.48%</td>
<td>74.06%</td>
<td>&lt;0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Number of days of work or other usual daily activities missed due to pneumonia</td>
<td>12.9, 8 [5–14]</td>
<td>9.8, 7 [4–14]</td>
<td>14.7, 10 [6–15]</td>
<td>&lt;0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Number of days until reached usual performance level in work or other usual daily activities</td>
<td>77.41%</td>
<td>80.83%</td>
<td>75.79%</td>
<td>0.208&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Percent with family or friends helping with care during pneumonia</td>
<td>45.19%</td>
<td>50.83%</td>
<td>37.99%</td>
<td></td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>P-value for percentage comparison; <sup>b</sup>P-value for mean comparison.

is persistent even after immunological response and control of the causative organisms. The magnitude and duration of host response may differ in different types of patients, with or without antibiotics.

For participants who reported that CAP worsened their comorbid conditions, many of the symptoms of these conditions were affected for more than a month; younger or hospitalized participants with worsened COPD were generally affected for more than 2 months. Our results are consistent with prior investigations showing that over 35% of adults with CAP at low risk of death have unresolved CAP-related symptoms 1 month post-diagnosis.

Our findings are also consistent with other studies showing: 1) older patients who survive CAP on average had similar symptoms but different severity or duration of symptoms than younger patients because of the former’s diminished ability to mount a robust immune response;<sup>19,20</sup> 2) CAP patients with other coexisting health conditions had significantly impaired general quality of life compared to CAP patients without underlying diseases;<sup>21</sup> and 3) a median time to return to work of 7 days for outpatients and 14 days for inpatients in low-risk CAP patients.<sup>8</sup> Although time to return to full work/activity productivity has not been assessed in previous studies, the 3 weeks needed to return to full productivity even after return to work highlights the impact of CAP beyond traditional productivity measures.

This study has some important limitations. As in previous recovery studies,<sup>6,22</sup> this study used retrospective recall of symptoms, which can be subject to recall bias.<sup>23,24</sup> To recruit a sufficient sample of older adults with CAP, a window of up to 120 days between diagnosis and Wave 1 survey completion was necessary. To address the issue of recall bias, prospective studies on the burden of CAP in patients who are surveyed soon after diagnosis are needed to assess the duration of specific CAP symptoms and functioning. Such studies are currently underway based on the work in this study.<sup>25</sup> The use of self-report for the diagnosis of pneumonia is also a limitation, although patients are likely to correctly remember a seminal event like the diagnosis of this potentially life-threatening illness.<sup>26,27</sup> We attempted to minimize case identification error by asking patients if they had a radiologically confirmed diagnosis – as radiography is another event that patients aged ≥50 years are likely to accurately recall.<sup>28–30</sup> Other studies have also used self-report of pneumonia diagnosis,<sup>31–33</sup> one of which showed high concordance (82%) between self-diagnosis and medical chart and radiographic confirmation of diagnosis.<sup>31</sup> Moreover, if there was overdiagnosis of pneumonia in the current study because of contamination by patients with bronchitis or other self-resolving disease, the results would most likely underestimate the burden of symptoms.<sup>34</sup> Another potential limitation that might bias the study results would be if the older adults with CAP in the YouGov® panel are different from the US general population for this age group in ways that cannot be fully adjusted for with the demographic weights that were used. Lastly, our study focused solely on CAP survivors and may not reflect the presence of symptoms at baseline in CAP patients who did not survive their bout with pneumonia. Therefore, there may be survivor bias in the comparisons of younger versus older patients and hospitalized versus nonhospitalized patients if older, hospitalized patients have greater mortality. Regardless, our results are accurate in terms of the clinical course of patients who will be seen in practice by clinicians, since they represent the population of survivors.

In addition, although CAP-BIQ captures data to provide a comprehensive picture of the course of illness and disease impact from the patient’s perspective, this lengthy
questionnaire may not be appropriate as an outcome measure in clinical trials testing treatment effects of various interventions for pneumonia. Nonetheless, the results from this patient-reported outcome questionnaire can inform the development of a shorter instrument for use in clinical trials measuring CAP impact at diagnosis and recovery. This work based on CAP-BIQ is the basis for ongoing studies to prospectively develop a patient-reported outcome for clinical trials in patients with radiographically confirmed CAP.\(^{37}\)

Despite these limitations, this study offers many key insights into patients’ experiences with CAP. A major strength of the study is the documentation of the content validity and understandability of the survey instrument before its use in this study, demonstrating a wide array of symptoms not captured in previous studies.\(^ {13}\) Moreover, few studies have examined the long-term effects of CAP beyond the first month after diagnosis. Employing a broad Web panel provided for nationwide enrollment. The use of a single method of administration for the survey also eliminates potential bias due to a mixing of methods (eg, Web survey, paper and pencil, etc). In addition, knowledge of the participants’ age, race/ethnicity, and education aided in the construction of post-stratification weights matching the US population aged \(\geq 50\) years, and corrected for any demographic skewness in the sample.

With this evidence from a patient perspective on the range of CAP symptoms, functional limitations, and time necessary to fully recover, our results can have an impact on clinical practice. Greater understanding of the natural history of CAP can aid both patients and clinicians in better managing episodes beyond the acute phase of the disease. Our data show a broader range of symptoms than cough, chest pain, and dyspnea, which are usually associated with pneumonia, indicating that clinicians should inquire about a broader range of symptoms. Symptoms often persist longer than a month, which exceeds the time when patients complete antibiotic therapy. Therefore, patients should be informed that they may continue to experience the residual effects of pneumonia long beyond the period of active treatment. Patient knowledge of the course of the treated disease allows for realistic expectations of the recovery trajectory, and may reduce unnecessary health care use and inappropriate antibiotic prescribing for apparent relapses that actually represent the natural course of the illness. A previous study reported greater pneumonia-related ambulatory care visits\(^ {6}\) with greater symptom burden during CAP recovery, independent of the pneumonia severity or comorbidities.

These results also demonstrate that adequate home care for a sufficient period is a key consideration, one that needs to be addressed either at the time of diagnosis (outpatient recovery) or during hospitalization prior to discharge. The seriousness and disability associated with CAP over an extended period is evidenced by 77% of the study population receiving informal care from family or friends for almost 2 weeks. Given that 30-day pneumonia readmission rate is tracked as an indicator of quality and coordination of care by the Center for Medicare and Medicaid Services,\(^ {33}\) providers should involve caregivers in the post-discharge planning and follow-up to reduce ambulatory care-sensitive readmissions.

Our results also provide evidence to inform future research efforts. Future studies may evaluate whether some treatments have greater effects than others in decreasing various symptoms associated with CAP. Current studies focus solely on resolution of a small number of early-resolving symptoms (eg, chest pain, cough, and dyspnea); yet the demand for patient-centered outcomes fully reflecting the patient’s experience has become a major impetus in health care reform.\(^ {36}\) Therefore, description of treatment effects on the spectrum of important CAP symptoms deserves further attention. Our results show a wider range of symptoms in pneumonia than are usually captured in clinician-reported outcomes in the clinical trials of CAP.

Finally, in addition to the substantial number of CAP deaths annually, this documented burden of illness among CAP survivors emphasizes the importance of CAP prevention in older adults to avoid the prolonged disability associated with this disease. Recommended prevention strategies include smoking cessation, annual influenza vaccination, pneumococcal vaccine for adults aged \(\geq 65\) years and those <65 years old who have underlying medical conditions, and educational support for these vulnerable populations.\(^ {37}\)

**Conclusion**

This study demonstrated that older adults surviving a CAP episode experience a significant multi-symptom illness with long recovery period before achieving pre-CAP health and productivity. These findings highlight the importance of communicating the natural course of the illness to inform patient and clinician expectations, the need for further research on effective clinician–patient communication, adequate home care during the recovery process, better patient-centered outcomes in evaluating therapies for CAP, and the pursuit of CAP prevention strategies.
Acknowledgments

The authors acknowledge the valuable assistance of Elizabeth Nicole Bush in the development and execution of this study, and Anna Steenrod in the development of this manuscript as paid employees of Evidera (formerly a division of United BioSource Corporation). This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009.

Author contributions

KWW had full access and control to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KWW also takes responsibility for the content of the manuscript, including the data and analysis. All four authors participated in the study design, data collection process, and analyses and interpretation, and agree to allow the journal to review their data if requested. All four authors participated in the manuscript writing, review, and approval to submit this paper to Patient Related Outcome Measures. Written permission was obtained from all corresponding authors prior to submission.

Disclosure

HY and RS are employees of Pfizer Inc. KWW is an employee of Evidera, Inc., formerly a division of United BioSource Corporation, which received financial support from Pfizer in connection with the study development and execution as well as the manuscript development. JHP was a paid clinical consultant to Pfizer in connection with the study development and execution as well as the manuscript development. JHP also serves as a paid employee of Evidera (formerly a division of United BioSource Corporation), which received financial support from Pfizer in connection with the study development and execution as well as the manuscript development. All four authors participated in the manuscript writing, review, and approval to submit this paper to Patient Related Outcome Measures. Written permission was obtained from all corresponding authors prior to submission.

Acknowledgments

The authors acknowledge the valuable assistance of Elizabeth Nicole Bush in the development and execution of this study, and Anna Steenrod in the development of this manuscript as paid employees of Evidera (formerly a division of United BioSource Corporation). This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009.

Author contributions

KWW had full access and control to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KWW also takes responsibility for the content of the manuscript, including the data and analysis. All four authors participated in the study design, data collection process, and analyses and interpretation, and agree to allow the journal to review their data if requested. All four authors participated in the manuscript writing, review, and approval to submit this paper to Patient Related Outcome Measures. Written permission was obtained from all corresponding authors prior to submission.

Disclosure

HY and RS are employees of Pfizer Inc. KWW is an employee of Evidera, Inc., formerly a division of United BioSource Corporation, which received financial support from Pfizer in connection with the study development and execution as well as the manuscript development. JHP was a paid clinical consultant to Pfizer in connection with the study development and execution as well as the manuscript development. JHP also serves as a paid employee of Evidera (formerly a division of United BioSource Corporation), which received financial support from Pfizer in connection with the study development and execution as well as the manuscript development. All four authors participated in the manuscript writing, review, and approval to submit this paper to Patient Related Outcome Measures. Written permission was obtained from all corresponding authors prior to submission.

References


